BRPI0924535B1 - Anticorpo direcionado a dois alvos e seu método de produção, dna, vetor de expressão recombinante e composição farmacêutica - Google Patents

Anticorpo direcionado a dois alvos e seu método de produção, dna, vetor de expressão recombinante e composição farmacêutica Download PDF

Info

Publication number
BRPI0924535B1
BRPI0924535B1 BRPI0924535-9A BRPI0924535A BRPI0924535B1 BR PI0924535 B1 BRPI0924535 B1 BR PI0924535B1 BR PI0924535 A BRPI0924535 A BR PI0924535A BR PI0924535 B1 BRPI0924535 B1 BR PI0924535B1
Authority
BR
Brazil
Prior art keywords
antibody
cancer
targets
dna
present
Prior art date
Application number
BRPI0924535-9A
Other languages
English (en)
Portuguese (pt)
Inventor
Jin San Yoo
Weon Sup Lee
Sung Woo Kim
Sang Ryeol Shim
Original Assignee
Pharmabcine Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmabcine Inc. filed Critical Pharmabcine Inc.
Publication of BRPI0924535A2 publication Critical patent/BRPI0924535A2/pt
Publication of BRPI0924535B1 publication Critical patent/BRPI0924535B1/pt

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Zoology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physics & Mathematics (AREA)
  • Pain & Pain Management (AREA)
BRPI0924535-9A 2009-05-20 2009-07-22 Anticorpo direcionado a dois alvos e seu método de produção, dna, vetor de expressão recombinante e composição farmacêutica BRPI0924535B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR10-2009-0044032 2009-05-20
KR1020090044032A KR101224468B1 (ko) 2009-05-20 2009-05-20 신규한 형태의 이중표적항체 및 그 용도
PCT/KR2009/004084 WO2010134666A1 (ko) 2009-05-20 2009-07-22 신규한 형태의 이중표적항체 및 그 용도

Publications (2)

Publication Number Publication Date
BRPI0924535A2 BRPI0924535A2 (pt) 2015-06-30
BRPI0924535B1 true BRPI0924535B1 (pt) 2021-07-20

Family

ID=43126324

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0924535-9A BRPI0924535B1 (pt) 2009-05-20 2009-07-22 Anticorpo direcionado a dois alvos e seu método de produção, dna, vetor de expressão recombinante e composição farmacêutica

Country Status (13)

Country Link
US (1) US10125194B2 (enExample)
EP (1) EP2433968B1 (enExample)
JP (2) JP5744012B2 (enExample)
KR (1) KR101224468B1 (enExample)
CN (1) CN102428104B (enExample)
AU (1) AU2009346447B2 (enExample)
BR (1) BRPI0924535B1 (enExample)
CA (1) CA2762555C (enExample)
DK (1) DK2433968T3 (enExample)
ES (1) ES2605604T3 (enExample)
RU (1) RU2520824C2 (enExample)
SG (1) SG175971A1 (enExample)
WO (1) WO2010134666A1 (enExample)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2668210T3 (da) 2011-01-26 2020-08-24 Celldex Therapeutics Inc Anti-kit antistoffer og anvendelser deraf
KR20120130658A (ko) * 2011-05-23 2012-12-03 주식회사 파멥신 펩타이드가 융합된 이중표적항체 및 그 용도
WO2013075740A1 (en) 2011-11-23 2013-05-30 Sanofi Antibody purification method
CA2856255C (en) 2011-11-23 2021-06-22 Bioven 3 Limited Recombinant proteins and their therapeutic uses
CN110256559B (zh) 2012-07-25 2023-05-26 塞尔德克斯医疗公司 抗kit抗体及其用途
ES2744267T3 (es) * 2012-11-21 2020-02-24 Pharmabcine Inc Anticuerpo de doble diana que se dirige a VEGFR-2 y DLL4, y composición farmacéutica que comprende el mismo
WO2014108854A1 (en) 2013-01-09 2014-07-17 Fusimab Ltd. Monospecific anti-hgf and anti-ang2 antibodies and bispecific anti-hgf/anti-ang2 antibodies
KR102049991B1 (ko) 2013-03-28 2019-12-02 삼성전자주식회사 항 c-Met/항 Her2 이중 특이 항체
KR102074421B1 (ko) 2013-03-29 2020-02-10 삼성전자주식회사 항 c-Met/항 EGFR 이중 특이 항체
KR102060540B1 (ko) 2013-04-03 2019-12-31 삼성전자주식회사 항 c-Met 항체 및 항 Ang2 항체를 포함하는 병용 투여용 약학 조성물
TWI631132B (zh) * 2013-05-06 2018-08-01 賽諾菲公司 用於純化抗體之連續多步驟方法
KR20150063728A (ko) * 2013-12-02 2015-06-10 삼성전자주식회사 항 VEGF-C/항 Ang2 이중 특이 항체
KR102223502B1 (ko) 2014-05-09 2021-03-05 삼성전자주식회사 항 c-Met/항 EGFR/항 Her3 다중 특이 항체 및 이의 이용
AR100271A1 (es) * 2014-05-19 2016-09-21 Lilly Co Eli Compuestos de vegfr2 / ang2
CN113908269A (zh) 2014-05-23 2022-01-11 塞尔德克斯医疗公司 嗜酸性粒细胞或肥大细胞相关病症的治疗
KR20160024639A (ko) 2014-08-26 2016-03-07 삼성전자주식회사 c-Met 표적 치료제의 저항성 또는 효능 예측을 위한 바이오마커 PDGF
WO2016060297A1 (ko) * 2014-10-16 2016-04-21 주식회사 파멥신 VEGFR-2 및 c-Met에 대하여 결합성을 갖는 이중표적항체
KR102309881B1 (ko) 2014-11-21 2021-10-06 삼성전자주식회사 c-Met 및 EGFR의 이중 저해제 및 IGF-1R 저해제를 포함하는 병용 투여용 약학 조성물
EA201890305A1 (ru) 2015-07-15 2018-07-31 Генмаб А/С Гуманизированные или химерные cd3-антитела
MX2018015853A (es) 2016-07-14 2019-08-21 Genmab As Anticuerpos multiespecificos frente a los grupos de diferenciacion 40 y 137 (cd40 y cd137).
EP3511341A4 (en) * 2016-09-08 2020-05-13 Woori Technologies Corporation DEGLYCOSILIZED ANTIBODY WITH SPECIFIC BINDING TO CLEC14A AND USES THEREOF
IL322509A (en) 2017-03-09 2025-10-01 Genmab As Antibodies against PD-L1
UA127586C2 (uk) 2017-03-31 2023-10-25 Ґенмаб Холдінґ Б.В. Біспецифічні анти-cd37-антитіла, моноклональні анти-cd37-антитіла та способи їх застосування
AU2018309339C1 (en) 2017-08-04 2025-08-21 BioNTech SE Binding agents binding to PD-L1 and CD137 and use thereof
US20210009695A1 (en) * 2018-03-19 2021-01-14 Pharmabcine Inc. Anti-vegfr-2 antibody
TWI813649B (zh) * 2018-03-20 2023-09-01 財團法人國家衛生研究院 可標靶ｖｅｇｆｒ２與ｖｅｇｆｒ３的雙功能抗體
CN119881293A (zh) 2018-03-21 2025-04-25 沃特世科技公司 基于非抗体高亲和力的样品制备、吸附剂、装置和方法
EP3546475A1 (en) 2018-03-27 2019-10-02 Sanofi Full flow-through process for purifying recombinant proteins
WO2020060405A1 (en) 2018-09-19 2020-03-26 Lava Therapeutics B.V. Dual acting cd1d immunoglobulin
BR112021006055A2 (pt) 2018-10-04 2021-07-20 Genmab Holding B.V. composição farmacêutica, uso da composição farmacêutica, e, métodos para induzir a morte celular ou para inibir o crescimento e/ou proliferação de uma célula tumoral e para tratar um indivíduo.
CN120983617A (zh) 2018-11-06 2025-11-21 健玛保 抗体配制剂
NL2022494B1 (en) 2019-02-01 2020-08-19 Lava Therapeutics B V Novel CD40-binding antibodies
CN113993893A (zh) 2019-02-01 2022-01-28 拉法医疗有限公司 新cd40结合抗体
MX2021012869A (es) * 2019-08-14 2021-12-10 Pharmabcine Inc Anticuerpo anti-tie2 y uso del mismo.
EP3792283A1 (en) 2019-09-16 2021-03-17 Lava Therapeutics B.V. Treatment of cancer comprising administration of vgamma9vdelta2 t cell receptor binding antibodies
WO2021155916A1 (en) 2020-02-04 2021-08-12 BioNTech SE Treatment involving antigen vaccination and binding agents binding to pd-l1 and cd137
KR20220154757A (ko) 2020-03-18 2022-11-22 젠맵 에이/에스 B7h4에 결합하는 항체
IL297986A (en) 2020-05-08 2023-01-01 Genmab As Bispecific antibodies against cd3 and cd20
IL299748A (en) 2020-07-08 2023-03-01 Lava Therapeutics N V Antibodies that bind PSMA and T gamma delta receptors
EP4192859A1 (en) 2020-08-06 2023-06-14 BioNTech SE Binding agents for coronavirus s protein
BR112023004321A2 (pt) 2020-09-10 2023-04-04 Genmab As Método para tratar linfoma de célula b grande difusa em um sujeito humano
JP2023541858A (ja) 2020-09-10 2023-10-04 ジェンマブ エー／エス 慢性リンパ球性白血病を治療するためのｃｄ３及びｃｄ２０に対する二重特異性抗体
CR20230204A (es) 2020-10-14 2023-10-11 Viridian Therapeutics Inc Composiciones y métodos para el tratamiento de la enfermedad ocular tiroidea
AU2021395439A1 (en) 2020-12-10 2023-06-22 LAVA Therapeutics N.V. Antibodies that bind gamma-delta t cell receptors
EP4298125A1 (en) 2021-02-26 2024-01-03 LAVA Therapeutics N.V. Antibodies that bind cd123 and gamma-delta t cell receptors
KR20240004949A (ko) 2021-05-07 2024-01-11 젠맵 에이/에스 B7h4 및 cd3에 결합하는 이중특이적 항체를 포함하는 제약 조성물
TW202315891A (zh) 2021-06-21 2023-04-16 丹麥商珍美寶股份有限公司 結合劑給藥排程
TW202320850A (zh) 2021-08-10 2023-06-01 美商維里迪恩醫療股份有限公司 用於治療甲狀腺眼病之組合物、劑量及方法
US20240409634A1 (en) 2021-09-13 2024-12-12 Janssen Biotech, Inc. CD33 x Vd2 MULTISPECIFIC ANTIBODIES FOR THE TREATMENT OF CANCER
MX2024003615A (es) 2021-10-08 2024-04-09 Genmab As Anticuerpos que se unen al cumulo de diferenciacion 30 (cd30) y al cumulo de diferenciacion 3 (cd3).
WO2023067138A1 (en) 2021-10-21 2023-04-27 LAVA Therapeutics N.V. Uses of gamma delta t cell activating antibodies
WO2023174521A1 (en) 2022-03-15 2023-09-21 Genmab A/S Binding agents binding to epcam and cd137
EP4285926A1 (en) 2022-05-30 2023-12-06 LAVA Therapeutics N.V. Combination treatment for chronic lymphocytic leukemia
EP4292609A1 (en) 2022-06-15 2023-12-20 LAVA Therapeutics N.V. Compositions comprising antibodies that bind gamma-delta t cell receptors
EP4292610A1 (en) 2022-06-15 2023-12-20 LAVA Therapeutics N.V. Variant antibodies that bind gamma-delta t cell receptors
NL2032398B1 (en) 2022-07-06 2024-01-23 Academisch Ziekenhuis Leiden Bispecific antibody and uses thereof
WO2024200573A1 (en) 2023-03-27 2024-10-03 LAVA Therapeutics N.V. Nectin-4 binding agents and methods of use
EP4438624A1 (en) 2023-03-27 2024-10-02 LAVA Therapeutics N.V. Antibodies that bind nectin-4 and gamma-delta t cell receptors
WO2024208898A1 (en) 2023-04-05 2024-10-10 Genmab A/S Pharmaceutical compositions comprising antibodies binding to cd30 and cd3
AR133071A1 (es) 2023-06-30 2025-08-20 Genmab As ANTICUERPOS QUE SE UNEN A LA PROTEÍNA DE ACTIVACIÓN DE FIBROBLASTOS a Y AL RECEPTOR DE MUERTE 4
WO2025012118A2 (en) 2023-07-07 2025-01-16 LAVA Therapeutics N.V. 5t4 binding agents and methods of use
WO2025024780A1 (en) 2023-07-27 2025-01-30 LAVA Therapeutics N.V. Antibodies that bind gamma-delta t cell receptors for the treatment of cancer
WO2025056180A1 (en) 2023-09-15 2025-03-20 BioNTech SE Methods of treatment using agents binding to epcam and cd137 in combination with pd-1 axis binding antagonists

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
JP2938569B2 (ja) 1990-08-29 1999-08-23 ジェンファーム インターナショナル，インコーポレイティド 異種免疫グロブリンを作る方法及びトランスジェニックマウス
WO1992009690A2 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with altered binding properties
ATE314479T1 (de) 1992-05-18 2006-01-15 Genentech Inc Aktivierung von rezeptoren fähig zur oligomerisierung durch verwendung von fusionierten rezeptor liganden
US5942602A (en) * 1997-02-13 1999-08-24 Schering Aktiengessellschaft Growth factor receptor antibodies
MXPA01010891A (es) * 1999-04-28 2002-11-07 Univ Texas Composiciones y metodos para el tratamiento contra el cancer mediante la inhibicion selectiva del factor de crecimiento endotelial vascular (vegf).
US7090843B1 (en) * 2000-11-28 2006-08-15 Seattle Genetics, Inc. Recombinant anti-CD30 antibodies and uses thereof
JP2005526506A (ja) 2002-03-04 2005-09-08 イムクローン システムズ インコーポレイティド Ｋｄｒに特異的なヒト抗体及びその利用
EP2090591A3 (en) * 2002-04-22 2009-10-28 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Antibodies, recombinant antibodies, recombinant antibody fragments and fusions mediated plant disease resistance against fungi
DK1601697T3 (da) 2003-02-28 2007-10-01 Lonza Biologics Plc Oprensning af antistof ved protein A- og ionbytningskromatografi
JP4635255B2 (ja) 2003-09-02 2011-02-23 独立行政法人産業技術総合研究所 抗体医薬
CN100503640C (zh) * 2004-07-08 2009-06-24 中国人民解放军军事医学科学院生物工程研究所 一种抗肿瘤融合蛋白及其编码基因与应用
WO2006005361A1 (en) * 2004-07-13 2006-01-19 Centre National De La Recherche Scientifique Peptides liable to bind to the tie2 receptor, nucleic acids encoding them, and their uses
US20060058311A1 (en) * 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
CN1884300A (zh) * 2005-06-24 2006-12-27 中国人民解放军军事医学科学院微生物流行病研究所 一种具有靶向功能的抗肝癌超抗原,其制备方法及用途
WO2008090958A1 (ja) 2007-01-24 2008-07-31 Kyowa Hakko Kirin Co., Ltd. ドメイン交換された遺伝子組換え抗体組成物
KR100883430B1 (ko) * 2007-06-13 2009-02-12 한국생명공학연구원 혈관내피성장인자 수용체를 중화하는 인간 단클론항체 및그 용도
KR102060540B1 (ko) * 2013-04-03 2019-12-31 삼성전자주식회사 항 c-Met 항체 및 항 Ang2 항체를 포함하는 병용 투여용 약학 조성물

Also Published As

Publication number Publication date
ES2605604T3 (es) 2017-03-15
CA2762555A1 (en) 2010-11-25
KR20100125033A (ko) 2010-11-30
EP2433968B1 (en) 2016-09-07
DK2433968T3 (en) 2016-12-19
CN102428104A (zh) 2012-04-25
RU2520824C2 (ru) 2014-06-27
KR101224468B1 (ko) 2013-01-23
JP5744012B2 (ja) 2015-07-01
WO2010134666A1 (ko) 2010-11-25
JP2015119705A (ja) 2015-07-02
EP2433968A1 (en) 2012-03-28
EP2433968A4 (en) 2012-12-05
CN102428104B (zh) 2015-03-04
US10125194B2 (en) 2018-11-13
SG175971A1 (en) 2011-12-29
BRPI0924535A2 (pt) 2015-06-30
AU2009346447A1 (en) 2011-12-01
CA2762555C (en) 2018-02-20
AU2009346447B2 (en) 2013-11-14
RU2011146088A (ru) 2013-06-27
JP2012527234A (ja) 2012-11-08
US20120065380A1 (en) 2012-03-15

Similar Documents

Publication Publication Date Title
ES2605604T3 (es) Anticuerpo de dirección doble de forma nueva y uso del mismo
JP6395791B2 (ja) ヒトタンパク質チロシンホスファターゼβ（ＨＰＴＰβ）に結合する抗体及びその使用
JP5324593B2 (ja) マクロファージ刺激タンパク質受容体（ｒｏｎ）の阻害およびその処置の方法
CN109438576B (zh) 一种抗人cd47单克隆抗体的制备及其应用
JP6328231B2 (ja) 抗ｖｅｇｆ抗体およびそれを含む癌または血管新生関連疾患を予防、診断、または治療するための医薬組成物
KR20100020967A (ko) 뉴로필린 단편 및 뉴로필린-항체 복합체의 결정 구조
JP2024504124A (ja) 新規の抗グレムリン１抗体
JP2024500839A (ja) 四価ＦＺＤ及びＷＮＴコレセプター（ｃｏ－ｒｅｃｅｐｔｏｒ）結合抗体分子並びにその使用
KR20120130658A (ko) 펩타이드가 융합된 이중표적항체 및 그 용도
TW202227509A (zh) 針對vegf及ang2之雙特異性結合分子
WO2016042050A1 (en) Antibodies binding to bmp4, and uses thereof
JP6074071B2 (ja) ＶＥＧＦＲ２／Ａｎｇ２化合物
CN118791607B (zh) 双特异性抗体及其应用
KR20240056422A (ko) 인간 안지오포이에틴-2에 특이적으로 결합하는 제1 항원 결합 부위를 포함하는 이중특이적 항체 및 그 응용
KR101631646B1 (ko) VEGFR-2 및 c-Met에 대하여 결합성을 갖는 이중표적항체

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 22/07/2009, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 16A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2841 DE 17-06-2025 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.